PCVX NASDAQ
Vaxcyte, Inc.
1W: -8.4%
1M: +4.1%
3M: +14.5%
YTD: +30.6%
1Y: +43.7%
3Y: +29.7%
5Y: +161.4%
$60.67
+0.70 (+1.17%)
Weekly Expected Move ±18.2%
$38
$49
$60
$71
$82
Credit Risk of going bust: lower than 79% of companies Debt: 1.2% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.08 (down 99.9%), Vaxcyte, Inc. would be worth roughly what it owes.
Total debt $115.4M against a stock market value of $9.55B.
Distance to default 9.41 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $57.7M (short-term plus half of long-term), stock volatility 53.6%; Altman Z'' 5.13. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.08 (down 99.9%), Vaxcyte, Inc. would be worth roughly what it owes.
Total debt $115.4M against a stock market value of $9.55B.
Distance to default 9.41 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $57.7M (short-term plus half of long-term), stock volatility 53.6%; Altman Z'' 5.13. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
19 relationships13
As Filer
counterparties named
6
As Counterparty
mentioned by others
3
Rel. Types
2022-04-18
Earliest Filing
2025-09-30
Latest Filing
partner: 8
supplier: 4
customer: 1
Counterparties (Filed by PCVX)
13 relationshipsCompanies named in PCVX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Patheon Manufacturing Services LLC | — | supplier | Master Services Agreement for formulation, fill, inspection, packaging, labeling, testing, and manufacturing of drug pro | 2025-09-30 | View |
| Thermo Fisher Scientific | TMO | partner | Parent company of Patheon Manufacturing Services LLC. | 2025-09-30 | View |
| ARE-San Francisco No. 63, LLC | — | partner | Landlord for the amended and restated lease agreement for corporate headquarters. | 2024-11-21 | View |
| Codexis, Inc. | CDXS | partner | Assignor of the lease rights for the expansion of headquarters. | 2024-11-21 | View |
| Iovance Biotherapeutics, Inc. | IOVA | customer | Sublessee of a portion of Suite 100A under a sublease agreement. | 2024-11-21 | View |
| Sutro Biopharma, Inc. | STRO | partner | Vaxcyte exercised an option to acquire manufacturing rights and exclusive rights to Sutro's cell-free extract technology | 2023-11-27 | View |
| Lonza Ltd | — | supplier | Agreement for construction, operation, and supply of manufacturing services for Vaxcyte's vaccine franchise. | 2023-10-16 | View |
| Sutro Biopharma, Inc. | STRO | partner | Vaxcyte entered into an option grant agreement and amended a license agreement with Sutro regarding cell-free extract ma | 2023-10-04 | View |
| Codexis, Inc. | CDXS | partner | Assignor in lease assignment agreement for Vaxcyte's headquarters expansion | 2023-09-07 | View |
| ARE-San Francisco No. 63, LLC | — | partner | Landlord in lease assignment agreement for Vaxcyte's headquarters expansion | 2023-09-07 | View |
| Lonza Ltd | — | supplier | Master Services Agreement for drug substances and microbial products development and manufacturing | 2023-03-06 | View |
| Sutro Biopharma, Inc. | STRO | partner | Vaxcyte entered into an option grant agreement to acquire authorization and rights to source Sutro's cell-free extract a | 2022-12-20 | View |
| Lonza Ltd | — | supplier | Master Services Agreement for drug product development and manufacturing | 2022-04-18 | View |
Mentioned As Counterparty
6 mentionsOther companies that named PCVX in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| IOVA IOVANCE BIOTHERAPEUTICS, INC. | customer | Counterparty to the New Headquarters Lease agreement for office space. | 2024-11-21 | View |
| STRO SUTRO BIOPHARMA, INC. | partner | Entered into an Option Agreement and Manufacturing Rights Agreement for exclusive manufacturing rights and license of ex | 2023-11-27 | View |
| STRO SUTRO BIOPHARMA, INC. | partner | License agreement amendment regarding cell-free extract manufacturing rights and royalty terms | 2023-10-04 | View |
| CDXS CODEXIS, INC. | supplier | Assigned lease obligations and premises from Codexis, Inc. | 2023-09-07 | View |
| STRO SUTRO BIOPHARMA, INC. | partner | Sutro Biopharma granted Vaxcyte authorization to source cell-free extract from an alternate CMO and an option to manufac | 2022-12-20 | View |
| STRO SUTRO BIOPHARMA, INC. | partner | Collaboration for VX-24 vaccine development | 2022-06-28 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-09 | Material Agreement; Financial Obligation; Other Events; Exhibits | Agreement | View |
| 2026-10-05 | Regulation FD; Other Events; Exhibits | View | |
| 2026-09-03 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-08-05 | Earnings Release; Exhibits | View | |
| 2026-07-15 | Officer/Director Change | View | |
| 2026-06-23 | Officer/Director Change | View | |
| 2026-06-16 | Shareholder Vote | View | |
| 2026-05-06 | Earnings Release; Exhibits | View | |
| 2026-02-24 | Other Events; Financial Statements and Exhibits | View | |
| 2026-02-24 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-02-02 | Other Events; Financial Statements and Exhibits | View | |
| 2025-12-19 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-11-04 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-09-30 | Entry into Material Definitive Agreement | Agreement | View |
| 2025-08-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-17 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-05-01 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-03-31 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-02-25 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR